Logo

Abstract

Aim and Objective: The aim and objective of the present study was to formulate and develop self-nanoemulsified liquisolid compacts of an antihypertensive biopharmaceutics classification system (BCS) Class II drug of felodipine which has poor aqueous solubility and low oral bioavailability (19.7 mg/L; log P, 4). Methodology: Felodopine was identified by ultraviolet–visible spectroscopy at λmax of 364 nm. A series of self-nanoemulsifying formulations F1-F9 were prepared using isopropyl myristate as oily phase, labrasol as surfactant and capmul C8 as cosurfactant, respectively. The prepared liquid self-nanoemulsifying system was solidified using solid carrier colloidal silicon dioxide (Aerosil 200). Initially, the solubility was examined in different oils, surfactants, and cosurfactant, and ternary phase diagrams were constructed to optimize the ratio of excipients having a greater microemulsion region. Results and Discussion: The self-nanoemulsified liquisolid compacts were developed and evaluated for droplet size determination, particle size distribution, dilution studies, and in vitro drug release studies. The in vitro dissolution studies revealed that the release patterns of the formulation (F2) containing 60% surfactant, 10% oil, and 30% cosurfactant show the least emulsification time and maximum drug release of 95% within 1 h concluding that the prepared self-emulsified liquisolid compacts with promising in vitro characteristics were expected to solve the oral delivery problems encountered for highly potent lipophilic drugs. Conclusion: The present study concluded that the prepared self-emulsified liquisolid compacts of felodipine were promising carriers to solve the oral delivery problems encountered for highly potent lipophilic drugs.

Abstract Audio

No Audio file found

About the authors and Affiliations

	Name
	JPR Solutions

View Article File in pdf format.

Article File

View Article Citation Here.

How to Cite my Article.

Experimental Methods Keywords